Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus rating of “Moderate Buy” by the nineteen ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $289.8889.

A number of equities analysts recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $260.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Bank of America reissued a “buy” rating and issued a $262.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, March 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Wedbush increased their price objective on Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research report on Wednesday, March 4th.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $229.25 on Friday. Ascendis Pharma A/S has a 52 week low of $124.06 and a 52 week high of $248.60. The company’s 50 day moving average price is $227.16 and its two-hundred day moving average price is $213.80. The company has a market capitalization of $14.29 billion, a P/E ratio of -52.10 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to the consensus estimate of $285.35 million. Analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S in the third quarter valued at $26,000. Arax Advisory Partners grew its holdings in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $42,000. Finally, Jones Financial Companies Lllp raised its holdings in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.